Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Obstructive Sleep Apnea Syndrome in Glaucoma
This study is currently recruiting participants.
Verified by University Hospital, Basel, Switzerland, January 2008
Sponsored by: University Hospital, Basel, Switzerland
Information provided by: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00313092
  Purpose

The aim of the study is to determine if plasma matrix-metalloproteinase activity can predict glaucoma in patients with OSAS and if the level of plasma matrix-metalloproteinase activity will decrease after one month of nCPAP-treatment.


Condition Intervention
Obstructive Sleep Apnoe Syndrome
Glaucoma
Device: nCPAP treatment

Genetics Home Reference related topics: early-onset glaucoma
MedlinePlus related topics: Glaucoma Sleep Apnea
U.S. FDA Resources
Study Type: Observational
Study Design: Case-Only, Prospective
Official Title: Does Plasma Matrix-Metalloproteinase Activity Predict Glaucomas in Patients With OSAS (Obstructive Sleep Apnea Syndrome) and Does the Level of Plasma Matrix-Metalloproteinase Activity Decrease After One Month of nCPAP-Treatment

Further study details as provided by University Hospital, Basel, Switzerland:

Biospecimen Retention:   None Retained

Biospecimen Description:

plasma


Estimated Enrollment: 60
Study Start Date: January 2005
Estimated Study Completion Date: September 2008
Intervention Details:
    Device: nCPAP treatment
    treatment with positive air pressure during night
Detailed Description:

Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The key feature of glaucoma is damage to the optic nerve head, which is not necessarily related to an increased intraocular pressure. The prevalence of glaucoma among the patients with sleep apnoea was 7,2%: normal-tension glaucoma 2,9%, primary open-angle glaucoma 4,3%. The prevalence of obstructive sleep apnoea syndrome (OSAS) is around 4-10% for men and 2-4% for women. Matrix metalloproteinases (MMPs) substrates include essentially all extracellular matrix components as well as a wide array of molecules involved in intracellular adhesion, cell-matrix interaction, and cell signalling. However, MMPs effects are not restricted to extracellular matrix degradation. The prevalence of increased MMP in patients with OSAS and its predicting value for an additional glaucoma are not known. Further, we do not know if treatment of OSAS with nasal continuous positive air pressure(nCPAP) can decrease the MMP activity. With this study, we want to determine the prevalence of MMP activity and the prevalence of glaucoma in patients with OSAS. Further, we want to investigate if a nCPAP treatment period of four weeks decreases the MMP activity.

  Eligibility

Ages Eligible for Study:   18 Years to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with sleep apnoe syndrom

Criteria

Inclusion Criteria:

  • OSAS planned begin of a nCPAP treatment

Exclusion Criteria:

  • Current malignancy
  • Oral steroids
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00313092

Contacts
Contact: Jörg D Leuppi, MD +41 61 265 8787 leuppij@uhbs.ch

Locations
Switzerland, BS
University Hospital Basel, Eye Clinic Recruiting
Basel, BS, Switzerland, 4031
Contact: Selim Orgül, MD     141 61 265 8787     sorguel@uhbs.ch    
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Study Director: Selim Orgül, MD University Eye Clinic Basel
  More Information

Responsible Party: University Hospital, Basel, Switzerland ( Selim Orgul )
Study ID Numbers: 045-LEJ-2004-002
Study First Received: April 10, 2006
Last Updated: January 14, 2008
ClinicalTrials.gov Identifier: NCT00313092  
Health Authority: Switzerland: Swissmedic

Keywords provided by University Hospital, Basel, Switzerland:
OSAS
glaucoma
MMP

Study placed in the following topic categories:
Sleep Apnea Syndromes
Respiratory Tract Diseases
Glaucoma
Apnea
Eye Diseases
Respiration Disorders
Sleep Apnea, Obstructive
Dyssomnias
Sleep Disorders
Sleep Disorders, Intrinsic
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:
Pathologic Processes
Disease
Syndrome
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009